Fig. 1: Clinical outcomes in first-line patients treated with immune checkpoint inhibitors (ICI) as monotherapy (ICI-mono, n = 300) or with chemotherapy (ICI-chemo, n = 375) in the MDACC primary cohort. | Nature Communications

Fig. 1: Clinical outcomes in first-line patients treated with immune checkpoint inhibitors (ICI) as monotherapy (ICI-mono, n = 300) or with chemotherapy (ICI-chemo, n = 375) in the MDACC primary cohort.

From: Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

Fig. 1

Comparison of a, progression-free survival (PFS) and b, overall survival (OS) between ICI-mono vs ICI-chemo. c, PFS in ICI-mono stratified by PD-L1. d PFS in ICI-chemo stratified by PD-L1. Hazard ratio (HR) and p values were calculated using unadjusted cox proportional hazards regression models. e Aalen’s additive hazard model on PFS and f on OS. Coefficient <0 favors ICI-chemo. Dashed gray lines indicate 95% confidence interval. Source data are provided as a Source Data file.

Back to article page